Innovate Biopharmaceuticals to Host Clinical and Scientific Update Event on Thursday, September 6, 2018, in New York City
August 03 2018 - 7:05AM
Innovate Biopharmaceuticals, Inc. (Nasdaq: INNT), a clinical stage
biotechnology company focused on developing novel therapeutics for
autoimmune and inflammatory diseases, announced that it plans to
host an event for members of the financial community on Thursday,
September 6, 2018, in New York from 8:15am-11:00am. The event
will be hosted by Innovate’s Scientific and Executive Management
Team. A formal invitation with further details will be sent in
advance of the event.
For further information about attending this event or to book an
individual appointment with Innovate’s management, please contact
Jennifer K. Zimmons, Ph.D., at +1 917.214.3514 or
jzimmons@innovatebiopharma.com.
Innovate intends to make available a live webcast and subsequent
replay of the event on its website. To access the webcast, please
visit the tab in the Events and Presentations section of Innovate’s
investor relations website.
About Innovate Biopharmaceuticals, Inc. (Nasdaq:
INNT): Innovate is a clinical stage biotechnology company
focused on developing novel therapeutics for immuno-inflammatory
diseases. Innovate’s lead drug candidate, larazotide acetate, has a
mechanism of action that renormalizes the dysfunctional intestinal
barrier by decreasing intestinal permeability and reducing antigen
trafficking, such as gliadin fragments in celiac disease, and
bacterial toxins and immunogenic antigens in NASH. In several
diseases, including celiac disease, NASH, Crohn’s disease,
ulcerative colitis, irritable bowel syndrome (IBS), type 1 diabetes
mellitus (T1DM), chronic kidney disease (CKD), the intestinal
barrier is dysfunctional with increased permeability.
In celiac disease, larazotide is the only drug which has
successfully met the primary endpoint with statistical significance
in a Phase 2b efficacy clinical trial (342 patients). Innovate
successfully completed the End of Phase 2 Meeting with the FDA in
2017 and is preparing to begin Phase 3 registration clinical trials
for celiac disease later in 2018. Larazotide has been exposed to
more than 800 subjects in clinical trials demonstrating a favorable
safety profile comparable to placebo for long-term chronic
administration. Larazotide has received Fast Track designation from
the FDA for celiac disease.
Forward Looking Statements This press release
includes forward-looking statements including, but not limited to,
statements related to our operations and business strategy. The
forward-looking statements contained in this press release are
based on management’s current expectations and are subject to
substantial risks, uncertainty and changes in circumstances. Actual
results may differ materially from those expressed by these
expectations due to risks and uncertainties, including, among
others, those related to our ability to obtain additional capital
on favorable terms to us, or at all, the success, timing and cost
of our drug development program and our ongoing or future clinical
trials, the lengthy and unpredictable nature of the drug approval
process, and our ability to commercialize our product candidates if
approved. These risks and uncertainties include, but may not be
limited to, those described in our Annual Report on Form 10-K filed
with the U.S. Securities and Exchange Commission (the “SEC”) on
March 14, 2018, as amended, our Quarterly Report on Form
10-Q filed with the SEC on May 15, 2018, and in any subsequent
filings we make with the SEC. Forward-looking
statements speak only as of the date of this press release, and we
undertake no obligation to review or update any forward-looking
statement except as may be required by applicable law.
SOURCE: Innovate Biopharmaceuticals, Inc.
Contact:Jennifer K. Zimmons, Ph.D.Tel: +1
917.214.3514jzimmons@innovatebiopharma.comwww.innovatebiopharma.com
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Aug 2024 to Sep 2024
Innovate Biopharmaceutic... (NASDAQ:INNT)
Historical Stock Chart
From Sep 2023 to Sep 2024